Literature DB >> 18425327

Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.

Roos Cuperus1, Godelieve A M Tytgat, René Leen, Pedro Brites, Johannes Bras, Huib N Caron, André B P Van Kuilenburg.   

Abstract

The efficacy and mechanism of action of fenretinide (4-HPR), a vitamin A analogue, was investigated in a panel of six neuroblastoma cell lines and multicellular tumor spheroids. The latter are three dimensional cell aggregates and as such, a model for micrometastases. In all cell lines, the production of reactive oxygen species (ROS) increased with 163-680% after 1 h of treatment with 4-HPR. In addition, a decrease of the mitochondrial membrane potential of 30-75% was observed after 4 h of incubation with 4-HPR. A 6-12-fold difference was observed between the IC50 values for cell proliferation and viability between the most sensitive (IMR32) and most resistant (NASS) cell line towards 4-HPR. Flow cytometric analysis showed an increased amount of apoptotic bodies and no cell-cycle arrest. The antioxidant Trolox completely inhibited the accumulation of 4HPR-induced ROS and prevented the 4HPR-associated cytotoxicity. In all neuroblastoma spheroids, 4-HPR induced a complete cytostasis at clinical relevant concentrations (3-10 microM). Immunohistochemical analysis of 4-HPR-treated spheroids showed a decreased staining for proliferation marker Ki-67 and an increased staining for cleaved-PARP, a marker of apoptosis. Our results suggest that 4-HPR might be a promising agent for the treatment of micrometastases and high-risk neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425327

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.

Authors:  Aintzane Apraiz; Jolanta Idkowiak-Baldys; Naiara Nieto-Rementería; María Dolores Boyano; Yusuf A Hannun; Aintzane Asumendi
Journal:  Biochem Cell Biol       Date:  2012-03-19       Impact factor: 3.626

2.  Nanoacetylated N-(4-Hydroxyphenyl) Retinamide Modulates Histone Acetylation-Methylation Epigenetic Disparity to Restrict Epithelial-Mesenchymal Transition in Neuroblastoma.

Authors:  Atul Dev; Mohammed Nadim Sardoiwala; Angela Sharma; Soni Jignesh MohanBhai; Surajit Karmakar; Subhasree Roy Choudhury
Journal:  ACS Med Chem Lett       Date:  2022-06-27       Impact factor: 4.632

3.  Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.

Authors:  Alessandra Marrella; Alessandra Dondero; Maurizio Aiello; Beatrice Casu; Daniel Olive; Stefano Regis; Cristina Bottino; Daniela Pende; Raffaella Meazza; Guido Caluori; Roberta Castriconi; Silvia Scaglione
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

4.  Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma.

Authors:  Roos Cuperus; René Leen; Godelieve A M Tytgat; Huib N Caron; André B P van Kuilenburg
Journal:  Cell Mol Life Sci       Date:  2009-11-26       Impact factor: 9.261

5.  Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.

Authors:  Barbara Bassani; Desirèe Bartolini; Arianna Pagani; Elisa Principi; Massimo Zollo; Douglas M Noonan; Adriana Albini; Antonino Bruno
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.